Lymphoma: all 5,624 studies

Page 41 of 57. Open to participants first (824), then studies with results posted, then the rest; newest registration first within each.

• Treatment of Natural Killer/T Cell Lymphoma-Ⅲ/ⅣStatus unknownNCT01501149Phase 4
• Treatment of Natural Killer/T Cell Lymphoma-I/IIStatus unknownNCT01501136Phase 4
• A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL)TerminatedNCT01500538Phase 2
• Infusion of Allogeneic CD19-Specific T Cells From Peripheral BloodCompletedNCT01497184Phase 1
• Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular LymphomaCompletedNCT01493479Phase 2
• Biomarkers in Blood and Tissue Samples From Patients With Epstein-Barr Virus-Positive Hodgkin LymphomaCompletedNCT01490801
• Single Dose of Intravenous rhTNF-α and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or LymphomasWithdrawnNCT01490047Phase 1
• Music Therapy on Nausea and Pain for Autologous Stem CellCompletedNCT01487031Not applicable
• A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell LymphomaCompletedNCT01486277Phase 2
• Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell LymphomaCompletedNCT01484093Phase 1/2
• Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile NeutropeniaCompletedNCT01484015Phase 1
• Rapid Rituximab Infusion at 90-minute Among Non-Hodgkin LymphomaCompletedNCT01482754Not applicable
• Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma PatientsCompletedNCT01481272Phase 2
• Zevalin Post-marketing Surveillance for Adequateness of Image Interpretation Criteria in JapanCompletedNCT01479387
• OPTIMAL>60 / DR. CHOP, Improvement of Therapy of Elderly Patients with CD20+ DLBCL Using Rituximab Optimized and Liposomal VincristineCompletedNCT01478542Phase 3
• Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline RegimenCompletedNCT01478269
• Prognosis of Patients With Relapsed/Refractory Hodgkin Lymphoma Treated With IGEV Induction Therapy Before HDCT With AHSCTCompletedNCT01478191
• CD19 CAR T Cells for B Cell Malignancies After Allogeneic TransplantCompletedNCT01475058Phase 1/2
• Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant LymphomaCompletedNCT01473095Phase 1
• SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) PatientsCompletedNCT01472887Phase 2
• Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's LymphomaCompletedNCT01471210Phase 1
• Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic MalignanciesCompletedNCT01471067Phase 1
• Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell LymphomaCompletedNCT01470456Phase 2
• Clinical Usefulness and Prognostic Significance of Interim 18F-FDG PET/CT for the Treatment of Peripheral T Cell LymphomasStatus unknownNCT01470066
• Longitudinal Survey Analysis in Lymphoma SurvivorsCompletedNCT01469754
• Prospective Study on HIV-related Hodgkin LymphomaStatus unknownNCT01468740Phase 2
• Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell LymphomaTerminatedNCT01466868Phase 2
• Outcomes of Cutaneous T-Cell Lymphoma and Graft-Versus-Host Disease With Extracorporeal Photopheresis TreatmentCompletedNCT01460914
• Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell LymphomaWithdrawnNCT01460602Phase 1/2
• A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic CancersCompletedNCT01460134Phase 1
• MELT - MRI Evaluation of Lymphoma TreatmentCompletedNCT01459224
• Nordic Study in Newly Diagnosed Primary Central Nervous System (CNS) LymphomaCompletedNCT01458730Phase 2
• Study of Mantle Cell Lymphoma Treatment by RiBVDCompletedNCT01457144Phase 2
• Bendamustine Plus Rituximab Versus Fludarabine Plus RituximabCompletedNCT01456351Phase 3
• Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin LymphomaCompletedNCT01453504Phase 1/2
• Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic MalignancyWithdrawnNCT01452334Phase 1
• Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCLStatus unknownNCT01449344Phase 3
• Zevalin Post-marketing Surveillance in JapanCompletedNCT01448928
• Study in Patients With Primary Breast Diffuse Large B-cell LymphomaCompletedNCT01448096Phase 2
• Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated DiseasesCompletedNCT01447056Phase 1
• R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic LymphomaTerminatedNCT01446900Phase 2
• Y90 Ibritumomab Tiuxetan Post R-CHOP Chemotherapy for Advanced Stage Follicular LymphomaCompletedNCT01446562Phase 2
• Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)Active, not recruitingNCT01446133Phase 2
• ABT-888 Plus Metronomic Cyclophosphamide to Treat CancerCompletedNCT01445522Phase 1
• Topical Romidepsin to Treat Early-Stage Cutaneous T-Cell LymphomaTerminatedNCT01445340Phase 1
• Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)Status unknownNCT01439750Phase 1
• A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL)CompletedNCT01435863Phase 1
• Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)Status unknownNCT01435720Phase 1/2
• In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell MalignanciesActive, not recruitingNCT01430390Phase 1
• Trial of Endostar Combined With CHOPT for T Cell LymphomaStatus unknownNCT01430013Phase 2
• Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin LymphomaCompletedNCT01429025Phase 1
• R-CVP for the Treatment of Non-conjunctival Ocular Adnexal MALT Lymphoma (OAML)CompletedNCT01427114Phase 2
• A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE)WithdrawnNCT01423539Phase 2
• Vorinostat in ChildrenCompletedNCT01422499Phase 1/2
• Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple MyelomaCompletedNCT01421524Phase 1
• Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid MalignanciesCompletedNCT01421173Phase 1
• Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL)CompletedNCT01419691Phase 2
• Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab)CompletedNCT01418430Phase 4
• MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell LymphomaWithdrawnNCT01415765Phase 1/2
• A Phase 1/2 Study of Lenalidomide in Combination With Bendamustine in Relapsed and Primary Refractory Hodgkin LymphomaStatus unknownNCT01412307Phase 1/2
• FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell LymphomaCompletedNCT01410630
• Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic LeukemiaCompletedNCT01410513Phase 1
• DNA Analysis in Influencing Response to Rituximab in Samples From Patients With Follicular Lymphoma Treated on ECOG-E4402CompletedNCT01406782
• Healthy Donor Study II - Comparing Plerixafor With G-CSF and PlerixaforCompletedNCT01403896Phase 2
• A Study of Investigational SAR245409 in Patients With Certain Lymphoma or LeukemiaCompletedNCT01403636Phase 2
• Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin LymphomaCompletedNCT01403415Phase 1
• SNP-Based Prediction of Oral Mucositis Risk in Patients Receiving Hematopoietic Stem Cell Transplants (HSCT)CompletedNCT01402687
• Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell LymphomaTerminatedNCT01402440Phase 1
• Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLLCompletedNCT01400685Phase 1
• Dual Point PET Scan in Early Stage Hodgkin Lymphoma Patients With Bulky LesionsStatus unknownNCT01399931
• Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular LymphomaCompletedNCT01393756Phase 2
• The First-in-human Phase I Trial of PU-H71 in Patients With Advanced MalignanciesCompletedNCT01393509Phase 1
• A Study of MabThera/Rituxan (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's LymphomaCompletedNCT01392716Phase 2
• Biomarkers in Tumor Tissue Samples From Patients With Peripheral T-cell Lymphoma or Natural Killer Cell NeoplasmsCompletedNCT01390597
• Escalating Doses of Torisel in Combination With Three Chemotherapies Regimens: R-CHOP, R-FC or R-DHA for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL).CompletedNCT01389427Phase 1/2
• A Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Non-Hodgkin's LymphomaCompletedNCT01388959Phase 2
• DIBH Proton PlanningCompletedNCT01386697
• NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT)CompletedNCT01386619Phase 1/2
• Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell LymphomaWithdrawnNCT01386398Phase 3
• Assessment of Cognitive Function in Breast Cancer and Lymphoma Patients Receiving ChemotherapyActive, not recruitingNCT01382082
• Biomarkers in Predicting Response to Rituximab Treatment in Samples From Patients With Indolent Follicular LymphomaCompletedNCT01381705
• Biomarker Expression in Samples From Young Patients With Anaplastic Large Cell LymphomaCompletedNCT01366170
• Protein Biomarker Levels in Tissue Samples From Young Patients With Low-risk Hodgkin LymphomaCompletedNCT01366157
• Unrelated Donor Stem Cell TransplantationCompletedNCT01364363Not applicable
• Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic LymphomaCompletedNCT01363817Phase 1
• Infusion of Allogeneic Umbilical Cord Blood-Derived Cluster of Differentiation Antigen 19 (CD19)-Specific T CellsCompletedNCT01362452Phase 1
• Early Treatment Stratification Based on PET Scan Response to Chemotherapy in Patients With Diffuse Large B-cell LymphomaCompletedNCT01361191Phase 2
• A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or LymphomaCompletedNCT01359696Phase 1
• Interim FDG PET/CT in Diffuse Large B Cell Lymphoma (DLBCL) PatientsStatus unknownNCT01357733Not applicable
• HD17 for Intermediate Stage Hodgkin LymphomaCompletedNCT01356680Phase 3
• Evaluating the Safety and Tolerability of GDC-0349 in Patients With Locally Advanced or Metastatic Solid Tumors or Non Hodgkin's LymphomaCompletedNCT01356173Phase 1
• A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell LymphomaWithdrawnNCT01355783Phase 3
• AZD1152 in Diffuse Large B-cell LymphomaCompletedNCT01354392Phase 1/2
• SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)Active, not recruitingNCT01352520Phase 2
• Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and LymphomaTerminatedNCT01352312Phase 1
• Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's MacroglobulinemiaCompletedNCT01351935Phase 1
• Study of CEP-9722 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell LymphomaCompletedNCT01345357Phase 1
• Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation CyclophosphamideCompletedNCT01342289Phase 1
• Safety and Tolerability Study of RAD001 and LBH589 in All Solid Tumors With Enrichment for EBV Driven TumorsStatus unknownNCT01341834Phase 1
• Retrospective Analysis of Skin/Soft Tissue Primary NK/T Cell LymphomaCompletedNCT01341119

← Lymphoma overview